Retatrutide
From $90.00
Triple-agonist peptide studied for its effects on GLP-1, GIP, and glucagon receptor pathways.




Description
Compound Specifications
| Compound class | Synthetic peptide — triple receptor agonist |
| Receptor targets (in vitro) | GLP-1R, GIPR, GCGR |
| Structural basis | GIP-based backbone with fatty acid modification |
| Form | Lyophilized powder |
| Available quantities | 5mg, 10mg, 20mg, 30mg, 40mg, 60mg per vial |
| Purity | ≥99% (HPLC verified) |
| Endotoxin testing | Performed per batch |
| Storage (lyophilized) | 2–8°C, protected from light |
| Storage (reconstituted) | 2–8°C, 30 days |
| Long-term storage | -20°C |
| Third-party testing | Freedom Diagnostics |
| Manufacturing | Arizona GMP facility, USA |
Molecular weight, molecular formula and CAS number to be populated from batch COA prior to publication.
Research Background
Retatrutide belongs to a class of engineered peptides described in the literature as multi-receptor agonists — single molecules designed to interact with more than one incretin-family receptor simultaneously. Where earlier compounds in this research area engaged a single receptor, and later dual agonists engaged two, Retatrutide is characterized as engaging three: the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor.
The structural approach involves a modified peptide backbone with a fatty acid chain attached, a design feature used across this compound class to extend circulating half-life through albumin binding. This is a formulation-level characteristic rather than a receptor-level one, and it is the reason compounds in this family are studied on extended dosing intervals in preclinical models.
The addition of glucagon receptor activity is what distinguishes Retatrutide from dual-agonist compounds in the same research area, and it is the principal variable examined in comparative preclinical literature.
Retatrutide is an investigational compound. It is not approved by the FDA or any other regulatory authority for any use. All references above describe published preclinical and laboratory research contexts. Noxa Labs makes no claim regarding safety, efficacy, or outcomes of any kind, in humans or animals.
Handling & Storage
Lyophilized Retatrutide is stable at 2–8°C when sealed and shielded from light. For storage beyond several months, -20°C is preferred. Avoid repeated freeze-thaw cycles, which degrade peptide integrity.
For solution preparation, introduce bacteriostatic water slowly down the inner wall of the vial rather than directly onto the powder — direct impact can shear the peptide chain. Swirl gently until fully dissolved. Do not shake or vortex. The resulting solution should be clear and free of particulates; cloudiness or visible precipitate indicates a handling failure and the vial should be discarded.
Fatty-acid-modified peptides are more sensitive to agitation than unmodified sequences. Handle accordingly.
Once in solution, store at 2–8°C and use within 30 days.
Concentration and volume calculator →
Purity & Testing
Every batch is synthesized at our GMP-compliant Arizona facility and independently analyzed by Freedom Diagnostics before release. We publish HPLC purity data and endotoxin testing results — we don’t ask you to take our word for it. Certificates of Analysis are available for any lot; contact us with your order number.
View all Certificates of Analysis →
Frequently Asked Questions
What receptors does Retatrutide act on?
Published literature characterizes it as an agonist at three receptors: GLP-1, GIP, and glucagon. This triple activity is what distinguishes it from single- and dual-agonist compounds in the same research class.
Is Retatrutide an approved medication?
No. Retatrutide is an investigational compound and is not approved by the FDA or any other regulatory authority for any use. This product is supplied for laboratory research purposes only.
What is the fatty acid modification for?
It is a half-life extension strategy common to this compound class. The fatty acid chain promotes albumin binding, which slows clearance in preclinical models.
What sizes are available?
5mg, 10mg, 20mg, 30mg, 40mg, and 60mg lyophilized vials.
How is it shipped and stored?
Lyophilized peptide is shelf-stable in transit and ships in discreet packaging from Arizona. Refrigerate at 2–8°C on arrival.
Is a Certificate of Analysis available?
Yes, for every lot. Contact us with your order number and we will provide the HPLC and endotoxin data for your specific batch.
Related Research Compounds
- Tesamorelin — GHRH analog, a separate research class
- MOTS-C — mitochondrial-derived peptide
- Certificates of Analysis — batch testing data
Research Use Only
For Research Use Only. This product is intended solely for laboratory research purposes. It is not a drug, food, or cosmetic and may not be misbranded, misused, or mislabeled as such. Retatrutide is an investigational compound not approved by the FDA for any indication. Not for human or veterinary use. Not for diagnostic or therapeutic use. Not for resale without authorization. No representation is made regarding safety or efficacy.
Additional information
| Strength | 5mg, 10mg, 20mg, 30mg, 40mg, 60mg |
|---|
Related products
-
✓ VerifiedUS ManufacturedGMP Certified Facility99% Purity3rd Party Tested
NAD+
0 out of 599% PUREUSA MADE3RD PARTY TESTED$180.00 Add to cart -
✓ VerifiedUS ManufacturedGMP Certified Facility99% Purity3rd Party Tested
BPC-157
0 out of 599% PUREUSA MADE3RD PARTY TESTED$90.00 Add to cart -
✓ VerifiedUS ManufacturedGMP Certified Facility99% Purity3rd Party Tested
Tesamorelin
0 out of 599% PUREUSA MADE3RD PARTY TESTEDFrom $100.00 Select options This product has multiple variants. The options may be chosen on the product page -
✓ VerifiedUS ManufacturedGMP Certified Facility99% Purity3rd Party Tested
TB-500
0 out of 599% PUREUSA MADE3RD PARTY TESTED$90.00 Add to cart

















